Chimeric Therapeutics (ASX:CHM) PB Ratio: (As of Jun. 24, 2026)


What is Chimeric Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Chimeric Therapeutics's share price is A$0.069. Chimeric Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was A$-0.07. Hence, Chimeric Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Chimeric Therapeutics's PB Ratio or its related term are showing as below:

During the past 5 years, Chimeric Therapeutics's highest PB Ratio was 1.68. The lowest was 0.02. And the median was 0.03.

ASX:CHM's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.83
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Chimeric Therapeutics's average Book Value Per Share Growth Rate was -63.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -74.50% per year.

During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Chimeric Therapeutics was -71.60% per year. The lowest was -74.50% per year. And the median was -73.05% per year.

Back to Basics: PB Ratio

Chimeric Therapeutics  (ASX:CHM) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Chimeric Therapeutics PB Ratio Related Terms

Chimeric Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics PB Ratio Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
PB Ratio
0.02 0.01 0.03 0.07 0.04

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.07 0.02 0.04 0.00

ASX:CHM vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Chimeric Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's PB Ratio falls into.


Chimeric Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Chimeric Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.069/-0.074
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PB Ratio=Market Cap /(Total Stockholders Equity-Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.